---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010529"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:49:31.124223+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# uniQure Q2 net loss $56.3M; restructures to cut 65% of workforce, burn by $75M/yr

## Summary
- Net loss $56.3M ($1.16 EPS) vs $68.5M ($1.44 EPS) in Q2 2023; revenue $11.1M up from $2.4M.
- Restructuring: 65% headcount reduction (~300 roles), sale of Lexington facility, $75M annual cash burn cut including $50M debt retirement.
- Cash $524M as of June 30, expected to fund operations through end 2027.
- FDA granted RMAT designation for AMT-130 in Huntington's; interim data showed dose-dependent slowing of disease progression and reduced NfL.
- Patient screening started for three new Phase I/II trials (AMT-260 mTLE, AMT-191 Fabry, AMT-162 SOD1 ALS); enrollment expected Q3 2024.

## SEC filing metadata
- accession: 0001558370-24-010529
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024010529/0001558370-24-010529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024010529/qure-20240801x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010529
- JSON: https://secwatch.observer/filing/0001558370-24-010529.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.